TTK Healthcare's 67th AGM revealed a 6% increase in revenue to Rs 801.49 crores and a significant jump in pre-tax profit to Rs 108.33 crores, including one-time income. EPS improved to Rs 57.79. The company maintained its dividend at Rs 10 per share. Performance varied across segments, with some showing growth while others faced challenges. The company has a strong cash balance of Rs 900 crores and expressed a positive outlook for the future, focusing on strategic initiatives across its diverse business portfolio.
TTK Healthcare's Q4 results show revenue growth to ₹1.90 billion, up 5.56% year-over-year. However, profitability declined with EBITDA falling to ₹120.00 million and net profit decreasing to ₹161.00 million. Despite challenges, the company declared a dividend of ₹10.00 per share.
02May 25
TTK Healthcare Faces Setback as USAID Cancels Condom Procurement Agreement
TTK Healthcare announced the cancellation of its agreement with Chemonics due to USAID's decision to stop condom procurement from the company. This has left TTK Healthcare with unsold inventory worth ₹58.60 million. The company plans to explore remedies, including potential legal action, to mitigate the impact of this contract cancellation.